These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 31593848)

  • 41. suPAR in cardiovascular disease.
    Montecillo J; Pirker T; Pemberton C; Chew-Harris J
    Adv Clin Chem; 2024; 121():89-131. PubMed ID: 38797545
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SuPAR, a potential inflammatory mediator in psoriasis pathogenesis.
    Hamie L; Eid E; Abbas O; Safi R; Nammour T; Tamim H; Makki M; Stephan C; Hasbani D; Wehbe H; Ghaoui N; Hawa M; Nasser N; Eid A; Kibbi AG; Kurban M
    Clin Exp Pharmacol Physiol; 2020 Oct; 47(10):1705-1712. PubMed ID: 32558953
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma.
    Kouhpayeh S; Andalib A; Gharagozloo M; Sanei MH; Esmaeil N; Maracy MR
    Adv Biomed Res; 2017; 6():108. PubMed ID: 28904936
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
    Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
    Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.
    McCabe NP; Angwafo FF; Zaher A; Selman SH; Kouinche A; Jankun J
    Oncol Rep; 2000; 7(4):879-82. PubMed ID: 10854562
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Soluble urokinase-type plasminogen activator receptor (suPAR) is elevated in caregivers of patients with parkinsonism.
    Joyce J; Cabanas N; Pisharody R; Ouyang B; Patel R; Reiser J; Hall DA; Witek N
    Parkinsonism Relat Disord; 2022 Aug; 101():39-42. PubMed ID: 35780693
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation.
    Rasmussen LJH; Petersen JEV; Eugen-Olsen J
    Front Immunol; 2021; 12():780641. PubMed ID: 34925360
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of urinary acidification function with the progression of diabetic kidney disease in patients with type 2 diabetes.
    Zhu H; Liu X; Zhang C; Li Q; An X; Liu S; Wu L; Zhang B; Yuan Y; Xing C
    J Diabetes Complications; 2019 Nov; 33(11):107419. PubMed ID: 31473080
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Salvianolic acid A attenuates steroid resistant nephrotic syndrome through suPAR/uPAR-αvβ3 signaling Inhibition.
    Li X; Qi D; Wang MY; Ji K; Xie QL; Wang Y; Du SH; Fan HY
    J Ethnopharmacol; 2021 Oct; 279():114351. PubMed ID: 34157324
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
    Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
    Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome.
    Hoenigl M; Raggam RB; Wagner J; Valentin T; Leitner E; Seeber K; Zollner-Schwetz I; Krammer W; Prüller F; Grisold AJ; Krause R
    Clin Biochem; 2013 Feb; 46(3):225-9. PubMed ID: 23159293
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma.
    Loosen SH; Tacke F; Püthe N; Binneboesel M; Wiltberger G; Alizai PH; Kather JN; Paffenholz P; Ritz T; Koch A; Bergmann F; Trautwein C; Longerich T; Roderburg C; Neumann UP; Luedde T
    Carcinogenesis; 2019 Aug; 40(8):947-955. PubMed ID: 30805627
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients.
    Risør LM; Binderup T; Fosbøl MØ; Andersen KF; Loft A; Friborg J; Kjaer A
    Sci Rep; 2022 Nov; 12(1):19126. PubMed ID: 36352036
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.
    Alfano M; Cinque P; Giusti G; Proietti S; Nebuloni M; Danese S; D'Alessio S; Genua M; Portale F; Lo Porto M; Singhal PC; Rastaldi MP; Saleem MA; Mavilio D; Mikulak J
    Sci Rep; 2015 Sep; 5():13647. PubMed ID: 26380915
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.
    Loosen SH; Breuer A; Tacke F; Kather JN; Gorgulho J; Alizai PH; Bednarsch J; Roeth AA; Lurje G; Schmitz SM; Brozat JF; Paffenholz P; Vucur M; Ritz T; Koch A; Trautwein C; Ulmer TF; Roderburg C; Longerich T; Neumann UP; Luedde T
    JHEP Rep; 2020 Apr; 2(2):100080. PubMed ID: 32140677
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
    Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
    Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Soluble Urokinase-Type Plasminogen Activator Receptor, Changes of 24-Hour Blood Pressure, and Progression of Chronic Kidney Disease.
    Jhee JH; Nam BY; Lee CJ; Park JT; Han SH; Kang SW; Park S; Yoo TH
    J Am Heart Assoc; 2021 Jan; 10(1):e017225. PubMed ID: 33325248
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
    Winnicki W; Sunder-Plassmann G; Sengölge G; Handisurya A; Herkner H; Kornauth C; Bielesz B; Wagner L; Kikić Ž; Pajenda S; Reiter T; Schairer B; Schmidt A
    Sci Rep; 2019 Sep; 9(1):13783. PubMed ID: 31551522
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
    Huang J; Liu G; Zhang YM; Cui Z; Wang F; Liu XJ; Chu R; Zhao MH
    BMC Med; 2014 May; 12():81. PubMed ID: 24884842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.